In the past 2 decades, the Childhood Cancer Survivor Study has also improved our understanding of the long-term mortality and morbidity in this high-risk population. In their seminal 1974 publication, Meadows and D’Angio 4 described the wide array of potential late effects of successful therapy for childhood cancer. The increasing number of survivors soon revealed acute and delayed modality-specific toxicities and their impact on quality of life and early mortality. 3 Consequently, the number of childhood cancer survivors is expected to increase as a result of the rising pediatric cancer incidence and improved long-term survival rates. 3 During this same period, the incidence of many histological subtypes of childhood cancer has increased, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia, non-Hodgkin lymphoma, neuroblastoma, and soft-tissue and germ-cell tumors. 2 In the United States, this success translates into >325 000 survivors of childhood cancer, of whom 24% are now >30 years from diagnosis. For all pediatric cancers, 5-year survival increased from 58% for children diagnosed between 19 to 82% for those diagnosed between 19. 1 Progress in cancer therapeutics over the past 40 years has remarkably improved survival rates for most childhood malignancies. Customer Service and Ordering InformationĬancer is diagnosed in >12 000 children and adolescents in the United States each year.
Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
